Toxicities of chemoradiotherapy and radiotherapy in nasopharyngeal carcinoma: an updated meta-analysis

Chun Wang1,*, Fei Wang2,*, Xin Min1, Qinfang Zhang1, Li-juan Shen3, Ying Jiang1 and Jun Yan1

Abstract
Objective: We investigated the risk of acute and late toxicities of concurrent chemoradiotherapy (CCRT) and radiotherapy alone in patients with nasopharynx carcinoma (NPC).

Methods: In this meta-analysis, we searched the PubMed, Embase, Cochrane Library, and Web of Science databases for eligible randomized clinical trials (RCTs). In addition to the incidence of specific toxicities, risk ratios (RRs) or odd ratios (ORs) and 95% confidence intervals (CIs) were obtained using fixed-effect or random-effects models.

Results: In total, 11 RCTs involving 2801 patients with NPC were included in this analysis. For grade ≥3 adverse events, patients who received CCRT treatment had a higher proportion of acute mucositis (39.9% vs. 30.5%, RR=1.30, 95%CI: 1.16–1.46) acute nausea and vomiting (RR=6.26, 95% CI: 2.01–19.45), and neutropenia (RR=30.86, 95% CI: 7.36 to 129.35). For late severe toxicities, CCRT treatment was significantly associated with higher incidence of hearing loss (116.56% vs. 411.43%, RR=1.461, 95%CI: 1.043–21.095). The incidence of acute nausea and vomiting was more frequent in patients receiving CCRT.

Conclusion: Compared with radiotherapy alone, CCRT increases the risk of severe acute toxicities (mucositis, nausea/vomiting, and neutropenia) and severe late toxicity (hearing loss) in patients with NPC. However, larger studies are needed to confirm this finding.

1Oncology Department, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai, China
2Department of Emergency Medicine, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai, China
3Department of Clinical Laboratory, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai, China

*These authors contributed equally to this work

Corresponding author:
Jun Yan, Oncology Department, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai, China.
Email: yanjun1040@126.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Keywords
Nasopharynx carcinoma, concurrent chemoradiotherapy, radiotherapy, acute and late toxic reactions, meta-analysis, randomized clinical trial

Date received: 29 January 2019; accepted: 28 May 2019

Introduction
Nasopharyngeal carcinoma (NPC) is a rare type of malignant carcinoma that has a specific geographical distribution and a high risk of distant metastases. In Southeast Asia, the annual incidence rate ranges from 0.15% to 0.5%. Radiotherapy is the cornerstone of initial treatment due to the radio-sensitivity of NPC and its deep-seated location. However, although radiotherapy alone is an efficacious treatment option for early-stage NPC, the prognosis of patients with locally advanced NPC remains unsatisfactory. Distant metastasis is the main cause of treatment failure in regionally advanced NPC. Since the publication of the findings of the 0099 (INT-0099) trial, concurrent chemoradiotherapy (CCRT) has been the standard therapy for locally advanced NPC, and further clinical trials have demonstrated that the 5-year overall survival (OS) rate for patients receiving CCRT is 11.7% higher than that for patients receiving radiotherapy alone. Recurrence-free survival and metastasis-free survival have also been shown to be improved in patients with NPC receiving CCRT. In addition, several other studies and meta-analyses have confirmed that CCRT confers additional benefits compared with radiotherapy alone.

Equally important is the frequency and type of adverse events associated with combination treatment of concurrent chemotherapy and radiotherapy. Severe toxicities can impair treatment compliance, diminish patient quality of life, and even be life-threatening. During radiotherapy, up to 95% of patients with NPC showed various levels of dosage-dependent acute dermatitis, contributing to increased risk of infection and delayed treatment. Furthermore, the combined activity of anti-neoplastic drugs and radiographic exposure may induce injuries to the oral mucosa and apoptosis of oral epithelial cells approximately 6–15 days after treatment initiation. Although several studies have investigated the toxicities of CCRT and radiotherapy, no study to date has compared these treatment modalities across almost all categories of acute and late severe (grade 3/4) adverse events in a large patient population.

The objective of the present meta-analysis, which includes almost all eligible randomized controlled trials (RCTs), was to comprehensively compare the incidence and risk of acute and late severe toxicities between CCRT and radiotherapy alone in a large sample size and to provide clinical evidence for the need for increased attention to toxicities in patients with NPC.

Methods and materials
Identification of studies
This meta-analysis was implemented on the basis of the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement. Relevant studies were identified by searching the PubMed, Embase, Cochrane Library, and Web of Science databases to a cut-off date of September 30, 2016, regardless of language.
or publication status. The search was conducted using the keywords “nasopharynx cancer or nasopharyngeal carcinoma or nasopharyngeal neoplasms”, “radiochemotherapy or chemoradiotherapy or chemoradiation or chemo-radiotherapy” and “toxicities or adverse event or side effect or adverse reaction or safety issue,” and was limited to human studies and clinical trials. The reference lists of relevant original and review articles were also manually searched to identify additional studies.

**Study inclusion and exclusion criteria**

Only RCTs in which CCRT was compared with radiotherapy alone in patients with NPC and in which detailed data on acute or late toxicities were reported were eligible for inclusion in the meta-analysis. Studies meeting the following additional standards were included: (1) endpoints regarding acute toxicities of CCRT and radiotherapy covering at least one of dysphagia, dermatitis, hearing loss, peripheral neuropathy, constipation, mucositis, and nausea and vomiting; (2) endpoints concerning late toxicities including at least one of xerostomia, dysphagia, mucositis, nasopharyngeal mucosal necrosis, otitis, hearing loss, brachial plexopathy, bone necrosis, temporal lobe necrosis, symptomatic brain damage, radiation-induced brain damage, radiation encephalopathy, endocrine dysfunction, visual toxicity, radiation-induced malignancy, secondary tumor, subcutaneous fibrosis, torrential bleeding, trismus, and spinal damage. Additionally, studies were excluded if they (1) were case reports, meeting abstracts, or editorial materials; or (2) were duplicated, incomplete, or outside of the range of the research topic.

**Data extraction**

Two reviewers independently extracted the data on study characteristics of CCRT and radiotherapy groups (e.g. sample size, ethnicity, and mean age of the study subjects), publication year, treatment arms, number of patients who suffered from acute or late toxicities, duration of follow up, and counts of acute and late toxicities. Where there was disagreement between the two reviewers, the opinion of a third reviewer was obtained.

**Statistical analysis**

The software R 3.3.1 (www.r-project.org) including the meta package was used for direct meta-analysis. First, a frequency table was generated to describe each toxicity item based on counts of toxic events or number of subjects with reported toxic events. The distinctions of dichotomous variables were statistically evaluated with the use of the risk ratio (RR) according to event frequency or odds ratio (OR) according to subject frequency with a two-tailed 95% confidence interval (CI). One fixed-effect model was established for consistent studies while a random-effects model was fitted for studies with heterogeneous results. Two-tailed \( P \) values <0.05 were considered statistically significant. Heterogeneity between the studies was evaluated by means of \( I^2 \) (if \( I^2 > 50\% \)) and the \( Q \) test of Cochran (if \( P < 0.10 \)). Both indices assess the percentage of variability across studies that is attributable to heterogeneity rather than to chance.

**Results**

**Search results and study characteristics**

Eleven eligible RCTs\(^6,10,21–29\) involving 2801 patients were included in the meta-analysis after excluding reviews, irrelevant studies, and duplicates. Figure 1 shows the details of the study selection process. Among the included studies, only two used intensity-modulated radiation therapy, while conventional irradiation was used in
the remaining studies. The main characteristics of the included studies are presented in Table 1. Patients were recruited between 1989 and 2008, and the median follow-up period was 35 months–7.3 years. The mean age of patients in the CCRT group in all studies was 42–50 years, while patients in the radiotherapy group were aged 44.3–52 years. The CCRT group received treatment including cisplatin, cisplatin complexes, 5-fluorouracil, oxaliplatin, and carboplatin, although the administration duration and dosage varied among the included studies. The prescribed dose among patients in the radiotherapy group was generally in the range of 60–70 Gy. Publication bias was not assessed in this meta-analysis as there were as many as ten toxicity endpoints with varying sample sizes included. The selected studies all featured
| First author/year [ref] | Inclusion period/ stage/ median follow-up | Group description/ patients, n | Mean age, years | Treatment 1 | Treatment 2 |
|------------------------|------------------------------------------|-------------------------------|----------------|-------------|-------------|
| Chen/201324            | 2002–2005/AJCC stage III–IVB/70 months   | RT/158                        | 46             |             |             |
|                        |                                          | CRT/158                       | 46             |             |             |
| Huang/201225           | 2002–2005/Chinese 1992 staging system stage III or IV/7.3 years | IC+CCRT/201                   | 42.7           | RT: carboplatin (AUC = 6) on days 7, 28, and 49 | IC: two cycles of fluorouridine (FuDR) + carboplatin (FuDR, 750 mg/m², days 1–5; carboplatin, AUC = 6) RT: 36–40 Gy in the first course and 66–78 Gy to the primary tumor and 60–70 Gy to the neck in the second course. Conventional fractionated radiotherapy (2 Gy once daily, 5 times per week) |
|                        |                                          | IC+RT/199                     | 43.3           |             |             |
| Lee/201026             | 1999–2004/AJCC stage T1–4 N2–3 M0/5 years | CCRT/172                      | 46             | CCRT: cisplatin (100 mg/m²) given intravenously every 3 weeks for three cycles starting with commencement of radiotherapy, followed by a combination of cisplatin (80 mg/m²) plus fluorouracil (1000 mg/m² per day by 96-hour infusion) every 4 weeks for three cycles | RT: ≥66 Gy (2 Gy/Fx/day, 5 Fx/week) |
|                        |                                          | RT/176                        | 47             |             |             |
| Chen/200728            | 2002–2005/AJCC stage T3–4 Nx M0 or Tx N2–3 M0/29 months | RT/158                        | 46             | RT: 68–70 Gy to the primary tumor, 60–62 Gy to involved areas of the neck, and 50 Gy to uninvolved areas | CRT/158 |
|                        |                                          | CRT/158                       | 46             |             |             |

(continued)
| First author/year [ref] | Inclusion period/ stage/ median follow-up | Group description/ patients, n | Mean age, years | Treatment 1 | Treatment 2 |
|------------------------|------------------------------------------|---------------------------------|----------------|-------------|-------------|
| Zhang/2005^10           | 2001–2003/AJCC stage T1–4 N0–3/24 months | RT/56 CCRT/59                   | 46.3           | (800 mg/m² intravenously) on days 1–5 by 120-h infusion for 3 cycles | RT: five times a week at 2 Gy/day on Monday through Friday |
|                       |                                          |                                 |                | CCRT: oxaliplatin 70 mg/m² weekly for six doses from the first day of RT |                         |
| Wee/2005^29            | 1997–2003/T3–4 Nx M0 or Tx N2–3 M0/3.2 years | RT/110 CCRT/111                 | 46             | CCRT: cisplatin (25 mg/m² on days 1–4) on weeks 1, 4, and 7 of RT | Standard-course RT: 70 Gy in 35 fractions (2 Gy per fraction) |
|                       |                                          |                                 |                | AC: cisplatin (20 mg/m² on days 1–4) and fluorouracil (1000 mg/m² on days 1–4) every 4 weeks (weeks 11, 15, and 19) for three cycles after completion of RT |                         |
| Lin/2003^31            | 1993–1999/AJCC stage T1–4 N0–3 overall III–IV (M0)/65 months | CCRT/141                        | 45             | CCRT: cisplatin 20 mg/m²/d in normal saline with fluorouracil (FU) 400 mg/m²/d as a 96-hour continuous infusion during weeks 1 and 5 of RT | RT: 70–74 Gy/7–8 weeks to the primary tumor and positive neck region and 50–60 Gy/5–6 weeks to the negative neck region |
| Chan/2002^32           | 1994–1997/Ho’s N2 or N3 stage or N1 stage with nodal size ≥4 cm/2.71 years | RT/143 CCRT/174                 | 48             | CCRT: cisplatin 40 mg/m² in 1 L of normal saline over 2 hours on a weekly basis during external radiotherapy, starting on the first day of radiotherapy | RT: 66 Gy in 33 fractions per 6.5 weeks |

(continued)
| First author/year [ref] | Inclusion period/ stage/ median follow-up | Group description/ patients, n | Mean age, years | Treatment 1 | Treatment 2 |
|-------------------------|------------------------------------------|-------------------------------|----------------|-------------|-------------|
| Al-Sarraf/1998<sup>6</sup> | 1989–1995/stage III and IV/2.7 years     | Control/69                     | 52             | CCRT: cisplatin 100 mg/m² on days 1, 22, and 43 during radiotherapy; chemotherapy with cisplatin 80 mg/m² on day 1 and fluorouracil 1000 mg/m²/d on days 1–4 administered every 4 weeks for three courses | RT: 1.8–2.0 Gy/day fractions, Monday to Friday for 35 to 39 fractions for a total dose of 70 Gy |
| Wu/2013<sup>23</sup>     | 2001–2003/AJCC stage T1–4 N0–3; WHO subtype II, or III NPC/114 months | Control/56                      | –              | CCRT: oxaliplatin 70 mg/m² delivered via intravenous infusion 1 h on day 1 every week | RT: The accumulated radiation doses to the primary tumor were 70–74 Gy. The accumulated doses were 60–64 Gy to the involved areas of the neck |
| Lee/2011<sup>27</sup>    | 1999–2004/T3–4 N0–1 M0/6.3 years         | CF/42                          | 49             | CRT: cisplatin 100 mg/m² intravenously every 3 weeks for 3 cycles starting with the commencement of RT, followed by a combination of cisplatin 80/m² plus fluorouracil 1000 mg/m²/day by 96-h infusion every 4 weeks for 3 cycles | RT: 2 Gy/Fx/day, 5 Fx/week |
|                          |                                          | AF/51                          | 48             |             | RT: 2 Gy/Fx/day, 6 Fx/week |
|                          |                                          | CF+C/52                        | 47             |             | RT: 2 Gy/Fx/day, 5 Fx/week |
|                          |                                          | AF+C/44                        | 50             |             | RT: 2 Gy/Fx/day, 6 Fx/week |
randomization to treatment arm, indicating that the data were likely to be robust (Table 2).

**Incidence and risk of specific acute toxicities**

For grade ≥3 toxicities, CCRT was significantly associated with higher incidence of mucositis (36.6% vs. 29%), nausea and vomiting (14.6% vs. 0.2%), and neutropenia (22.8% vs. 0.3%). According to subject frequency, all patients experienced any grade toxicities, and more patients experienced grade ≥3 nausea and vomiting in the CCRT group. In the radiotherapy alone group, no patient experienced grade ≥3 nausea and vomiting (Table 3).

As shown in Figure 2, CCRT significantly increased the risk of acute mucositis, whether assessed by event frequency (RR=1.26, 95% CI: 1.10–1.44, \(P<0.001\)) or subject frequency (RR=1.62, 95% CI: 1.05–2.50, \(P=0.029\)). Furthermore, CCRT significantly increased the risk of acute nausea/vomiting (RR=31.28, 95% CI: 7.70–127.06, \(P<0.001\)) and acute neutropenia (RR=55.85, 95% CI: 11.20–278.58, \(P<0.001\)) when compared with radiotherapy alone. No significant differences were observed between the groups in the risk of acute dermatitis and acute hepato-renal dysfunctions.

**Incidence and risk of specific late toxicities**

For late grade ≥3 toxicities, the event frequency of hearing loss (20.6% vs. 13.5%), mucositis (45.4% vs. 31.0%), and neutropenia (13.5% vs. 0%) was significantly higher in the CCRT group (Table 4). Our meta-analysis showed that CCRT was significantly associated with elevated risk of late severe hearing loss (RR=1.52, 95% CI: 1.03–2.25, \(P=0.037\)) compared with radiotherapy (Figure 3). For grade ≥3 xerostomia, the incidence in the CCRT group and the radiotherapy alone group was 5.8% and 2.4%, respectively, and the difference between the groups was not significant.

**Discussion**

To the best of our knowledge, this is the first meta-analysis that comprehensively compares the incidence and risk of severe acute and late toxicities associated with CCRT versus radiotherapy alone in a large population of patients with NPC. This meta-analysis included 11 RCTs,

---

**Table 2. Risk for bias assessment in selected randomized controlled trials**

| Authors/year | Concealed randomization | Stopped early | Participants blinded | Health-care providers blinded | Data collectors blinded | Outcome assessors blinded |
|--------------|-------------------------|---------------|---------------------|-----------------------------|------------------------|--------------------------|
| Chen/2013    | Yes                     | No            | Yes                 | Yes                         | Yes                    | Yes                      |
| Huang/2012   | Yes                     | No            | Not specified       | Not specified               | Not specified          | Not specified            |
| Lee/2010     | Yes                     | No            | Not specified       | Not specified               | Not specified          | Not specified            |
| Chen/2007    | Yes                     | No            | Not specified       | Not specified               | Not specified          | Yes                      |
| Zhang/2005   | Not specified           | No            | Not specified       | Not specified               | Not specified          | Not specified            |
| Wee/2005     | Yes                     | No            | Not specified       | Not specified               | Not specified          | Not specified            |
| Lin/2003     | Not specified           | No            | Not specified       | Not specified               | Not specified          | Not specified            |
| Chan/2002    | Yes                     | No            | Not specified       | Not specified               | Not specified          | Not specified            |
| Al-Sarraf/1998 | Not specified         | No            | Not specified       | Not specified               | Not specified          | Not specified            |
| Lee/2011     | Not specified           | No            | No                  | Not specified               | Not specified          | Not specified            |
| Wu/2013      | Not specified           | No            | Not specified       | Not specified               | Not specified          | Not specified            |
Table 3. Summary of acute toxicities (grade 3/4 and any grade)

| No. of studies | Treatment group | No. of | ≥3 grade | Any grade | P value for |
|----------------|-----------------|--------|----------|-----------|------------|
|                | Parallel chemoradiotherapy |          |          |           |            |
|                | Radiotherapy alone |        |          |           |            |
|                |                  | Concurrent chemoradiotherapy | Radiotherapy alone |          |            |
|                |                  | ≥3 grade | Any grade | ≥3 grade | Any grade |          |
| By event frequency |                  |          |          |           |            |
| Mucositis$^{24,26,27}$ | 4                | 229/626 (36.6%) | –         | 182/627 (29.0%) | –         | 0.0047 |
| Dysphagia$^{24}$          | 1                | 1/158 (0.6%) | –         | 0/158 | –         | >0.9999 |
| Ear deafness$^{27}$       | 1                | 4/95 (4.2%) | –         | 0/94 | –         | 0.1210 |
| Liver and kidney dysfunction$^{26,27}$ | 2 | 4/277 (1.4%) | –         | 0/270 | –         | 0.1238 |
| Nausea and vomiting$^{24,26,27}$ | 3 | 62/425 (14.6%) | –         | 1/428 (0.2%) | –         | <0.0001 |
| Neutropenia$^{24,26}$     | 2                | 82/334 (22.8%) | –         | 1/334 (0.3%) | –         | <0.0001 |
| Peripheral neuropathy$^{27}$ | 1 | 0/95 | –         | 1/94 (1.1%) | –         | 0.4974 |
| Radioactive skin reaction$^{24,26,27}$ | 3 | 64/425 (15.1%) | –         | 50/428 (11.7%) | –         | 0.1473 |
| By subject frequency |                  |          |          |           |            |
| Mucositis$^{10,31}$      | 3                | 76/259 (29.3%) | 259/259 (100.0%) | 56/255 (22.0%) | 255/255 (100.0%) | 0.0289 |
| Dysphagia$^{10}$          | 2                | 0/118 | 118/118 (100.0%) | 0/112 | 112/112 (100.0%) | – |
| Nausea and vomiting$^{31,32}$ | 2 | 27/315 (8.6%) | 315/315 (100.0%) | 0/319 | 319/319 (100.0%) | < 0.0001 |
Figure 2. Forest plot comparing acute toxicities between CCRT and radiotherapy alone according to event frequency of grade 3/4 mucositis (a); subject frequency of grade 3/4 mucositis (b); event frequency of grade 3/4 nausea and vomiting (c); and event frequency of grade 3/4 neutropenia (d). Size of the data square marker indicates the weight of each study in this analysis. The diamond represents the overall estimated effects in the model. CCRT: concurrent chemoradiotherapy; CI: confidence interval; OR: odds ratio; RR: risk ratio.
| Treatment group | No. of studies | By event frequency | Concurrent chemoradiotherapy | Radiotherapy alone | P value for ≥3 grade |
|----------------|---------------|--------------------|-----------------------------|--------------------|---------------------|
|                |               | ≥3 grade          | Any grade                  | ≥3 grade          | Any grade           |
| Hearing loss²⁴,²⁷ | 2             | 52/253 (20.6%)    | –                           | 34/252 (13.5%)    | –                   | 0.0438              |
| Dysphagia²⁴,²⁷   | 2             | 2/267 (0.7%)      | –                           | 0/270             | –                   | 0.2467              |
| Mucositis²⁸,²⁹   | 2             | 122/269 (45.4%)   | –                           | 83/268 (31.0%)    | –                   | 0.0006              |
| Mucositis²⁶      | 1             | 4/172 (2.3%)      | –                           | 1/176 (0.5%)      | –                   | 0.2108              |
| Otis²⁶           | 1             | 37/172 (21.5%)    | –                           | 27/176 (15.3%)    | –                   | 0.1374              |
| Peripheral neuropathy²⁵-²⁷ | 3 | 7/425 (1.6%) | –                           | 2/428 (0.5%) | –                   | 0.1065              |
| Cranial neuropathy²⁴,²⁶,²⁷ | 3 | 15/425 (3.5%) | –                           | 15/428 (4.3%) | –                   | >0.9999             |
| Brachial plexopathy²⁶,²⁷ | 2 | 0/267          | –                           | 2/270 (0.7%) | –                   | 0.4991              |
| Bone necrosis²⁴,²⁶ | 2 | 2/330 (18.2%) | –                           | 0/334             | –                   | 0.2466              |
| Temporal lobe Necrosis²⁴,²⁷ | 1 | 6/253 (2.3%) | 9/252 (3.5%) | –                   | 0.4271              |
| Fibrosis²⁴,²⁶,²⁷ | 3 | 19/425 (4.5%) | 15/428 (35.0%) | –       | 0.4709              |
| Symptomatic brain damage²⁴ | 1 | 1/158 (0.6%) | –                           | 1/158 (0.6%) | –                   | >0.9999             |
| Endocrine dysfunction²⁴,²⁷ | 2 | 16/267 (59.9%) | 13/270 (4.8%) | –                   | 0.5460              |
| Visual toxicity²⁴,²⁷ | 2 | 3/253 (1.2%) | 2/252 (0.8%) | –                   | >0.9999             |
| Radiation-induced malignancy²⁴,²⁶ | 2 | 0/330 | 1/334 (0.3%) | –                   | >0.9999             |
| Spinal damage²⁴  | 1             | 0/158            | –                           | 0/158             | –                   |                      |
| Neutropenia⁷-⁹   | 1             | 15/111 (13.5%)   | –                           | 0/110             | –                   | <0.0001             |
| Nausea and vomiting²⁹ | 1 | 1/111 (0.9%) | –                           | 0/110             | –                   | >0.9999             |
| Brainstem damage²⁶ | 1 | 0/172          | –                           | 1/176 (0.6%) | –                   | >0.9999             |
| Vascular occlusion²⁶ | 1 | 1/172 (0.6%) | –                           | 0/176             | –                   | 0.4943              |
| By subject frequency |               |                   |                             |                    |                      |
| Mucositis¹⁰      | 1             | 0/59             | 59/59 (100.0%) | 0/56   | 56/56 (100.0%) | –                   |
| Hearing loss⁶    | 1             | 9/78 (11.5%)     | 61/78 (78.2%) | 3/69   | 54/69 (78.3%) | 0.1120              |
| Nausea and vomiting⁶ | 1 | 14/78 (17.9%) | 39/78 (50.0%) | 5/69   | 46/69 (66.7%) | 0.0536              |
| Total late toxicities¹⁰ | 1 | 17/59 (28.8%) | 59/59 (100.0%) | 11/56 | 56/56 (100.0%) | 0.2521              |
with 2801 patients in total, to compare the toxicities associated with these two treatment modalities. By evaluating the incidence of five subtypes of acute toxicity (mucositis, nausea and vomiting, neutropenia, dermatitis, and hepato-renal function) and four subtypes of late toxicity (cranial neuropathy, hearing loss, peripheral neuropathy, and fibrosis of the neck), we showed that CCRT was associated with more severe acute mucositis, acute nausea/vomiting, acute neutropenia, and late hearing loss than radiotherapy alone. Among the enrolled studies, the median follow-up varied from 35 months to 7.3 years, durations which were appropriate for the analysis of late toxicities. In the present study, toxicities were the primary endpoint, and data on acute, late, and severe toxicities associated with CCRT and radiotherapy were recorded and analyzed to produce a comprehensive analysis of the types and severity of toxicities associated with CCRT and radiotherapy.

For acute toxicities, including grade 3/4 acute toxicities, this meta-analysis showed that CCRT was associated with higher risk of acute mucositis and nausea compared with radiotherapy, consistent with previous reports. The duration and severity of mucositis caused by radiotherapy have been closely correlated with the integrated action of accumulated dose, radioactive source, irradiation volume of mucosa, dose intensity, and xerostomia. Endothelial tissues and epithelium of connective tissues are damaged during radiotherapy, and the release of inflammatory factors such as prostaglandins, tumor necrosis factor, and interleukin-1 can aggravate tissue injury. Somewhat distinct from radiotherapy, mucositis induced by chemotherapy is mainly attributable to the route of administration, dose intensity, duration of therapy, and chemotherapeutic drug used. Normal DNA synthesis can be affected by chemotherapy, and the repeated and continuous usage of low-dose cytotoxic agents can further exacerbate the risk of mucositis. Therefore, CCRT appeared to promote the development of oral mucositis to a greater extent than radiotherapy alone. In clinical practice, anti-neoplastic drugs are typically administered 1 week after initiation of radiotherapy, leading to further injury to the oral mucous epithelium and associated formation of anabrosis.

For late toxicities, our meta-analysis showed that CCRT was significantly associated with late grade 3/4 hearing loss, consistent with previous reports. The inclusion of studies that used discrepant chemotherapeutic regimens for treating patients with NPC might have affected the
credibility of this association. Thus, the meta-analysis considered only the general outcomes of chemotherapy and the findings may therefore be inapplicable to specific medications. Any one of these chemotherapeutic studies may inevitably have over- or underestimated the association between CCRT and risk of late hearing loss.

Two of the included RCTs reported cases of bone necrosis when comparing CCRT with radiotherapy (1:04 and 1:17). No further evaluation of this finding was carried out because of the small number of RCTs included. Furthermore, a study by Lee et al.37 in 2013 found that concurrent chemotherapy was not associated with a significant increase in the risk of bone necrosis. Future studies in larger populations are needed to further explore these observations.

This study was limited by a lack of heterogeneity as all included studies enrolled only subjects of Chinese Han ethnicity, meaning that it may be difficult to generalize the results to other populations. In addition, there might be potential mutations that could affect the efficacy of CCRT. For instance, it was reported that non-small-cell lung cancer (NSCLC) patients who carried epidermal growth factor receptor (EGFR) mutations (e.g. exon 19 deletions and the L858R point mutation) could achieve better efficacy after treatment of gefitinib than those with normal EGFR genotypes.38,39 As a result, further molecular studies should be explored to discover potential mutations that might influence NPC patients' responses to different drugs.

There is increasing evidence that, compared with radiotherapy alone, CCRT may improve survival among patients with locally advanced NPC, and CCRT is thus commonly used in clinical practice. For patients at high risk of developing severe toxicities associated with CCRT such as mucositis, nausea and vomiting, and hearing loss should therefore be followed more closely when receiving CCRT.

Conclusions
The current study is the first meta-analysis to comprehensively and intensively analyze and compare acute and late toxicities between CCRT and radiotherapy alone. The findings indicate that CCRT is more likely to induce certain acute severe toxicities (e.g. acute mucositis and acute nausea and vomiting) and late severe toxicity (i.e. hearing loss) than radiotherapy. However, larger studies in more diverse populations are required to stratify patients with NPC by disease grade and specific mutations, and to subsequently compare the incidences of acute and late toxicities after treatment with CCRT or radiotherapy alone.

List of abbreviations
CCRT: concurrent chemoradiotherapy; CI: confidence interval; EGFR: epidermal growth factor receptor; NPC: nasopharynx carcinoma; NSCLC: non-small-cell lung cancer; OR: odd ratio; OS: overall survival; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-analysis; RCT: randomized clinical trial; RR: risk ratio

Acknowledgements
The authors wish to thank Professor Ming Ye from the radiotherapy department of Renji Hospital, affiliated to Shanghai Jiao Tong University. We also thank May Dong, Iris Sun, Sam Zhong, and Cuiling Yin for their assistance.

Availability of data and material
The data extracted and analyzed during the current study are available from the corresponding author upon reasonable request.

Declaration of conflicting interests
The authors declare that there is no conflict of interest.

Ethical approval
This article does not contain data from any studies with human participants or animals performed
by any of the authors. As the present study was a meta-analysis of published literatures, the study was exempt from Ethics Committee approval.

**Funding**

This study was funded by Shanghai Jiading District Science & Technology Commission (KWKYXM, 2014-KW-01) and the Seed Fund (Natural Science Class) of Shanghai University of Medicine & Health Sciences (no. HMSF-17-21-026).

**ORCID iD**

Chun Wang [https://orcid.org/0000-0002-8908-9501](https://orcid.org/0000-0002-8908-9501)

**References**

1. Wee JT, Ha TC, Loong SL, et al. Is nasopharyngeal cancer really a “Cantonese cancer”? *Chin J Cancer* 2010; 29: 517–526.
2. Tham IW, Hee SW, Yeo RM, et al. Treatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy—the national cancer centre singapore experience. *Int J Radiat Oncol Biol Phys* 2009; 75: 1481–1486.
3. Zhang L, Zhao C, Ghimire B, et al. The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase III randomized trials. *BMC Cancer* 2010; 10: 558.
4. Lee AW, Ma BB, Ng WT, et al. Management of nasopharyngeal carcinoma: current practice and future perspective. *J Clin Oncol* 2015; 33: 3356–3364.
5. Wong FC, Ng AW, Lee VH, et al. Whole-field simultaneous integrated-boost intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma. *Int J Radiat Oncol Biol Phys* 2010; 76: 138–145.
6. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. *J Clin Oncol* 1998; 16: 1310–1317.
7. Yang AK, Liu TR, Guo X, et al. Concurrent chemoradiotherapy versus radiotherapy alone for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis. *Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi* 2008; 43: 218–223.
8. Langendijk JA, Leemans CR, Buter J, et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. *J Clin Oncol* 2004; 22: 4604–4612.
9. Chan AT, Leung SF, Ngan RK, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. *J Natl Cancer Inst* 2005; 97: 536–539.
10. Zhang L, Zhao C, Peng PJ, et al. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. *J Clin Oncol* 2005; 23: 8461–8468.
11. Baujat B, Audry H, Bourhis J, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. *Int J Radiat Oncol Biol Phys* 2006; 64: 47–56.
12. Saleh-Ebrahimi L, Zwicker F, Muenter MW, et al. Intensity modulated radiotherapy (IMRT) combined with concurrent but not adjuvant chemotherapy in primary nasopharyngeal cancer - a retrospective single center analysis. *Radiat Oncol* 2013; 8: 20.
13. Greenspan D. Oral complications of cancer therapies. Management of salivary dysfunction. *NCI Monogr* 1990; 9: 159–161.
14. Su Z, Mao YP, Tang J, et al. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study. *Tumour Biol* 2016; 37: 4429–4438.
15. Du CR, Ying HM, Kong FF, et al. Concurrent chemoradiotherapy was associated with a higher severe late toxicity rate in nasopharyngeal carcinoma patients compared with radiotherapy alone: a meta-analysis based on randomized controlled trials. *Radiat Oncol* 2015; 10: 70.
16. Song Y, Wang W, Tao G, et al. Survival benefit of induction chemotherapy in treatment for locally advanced nasopharyngeal carcinoma–A time-to-event meta-analysis. *Oral Oncol* 2015; 51: 764–769.

17. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009; 339: b2700.

18. Schwarzer G, Carpenter JR and Rücker G. *Meta-analysis with R (Use-R!)*. Switzerland: Springer International Publishing, 2015.

19. Peters JL, Sutton AJ, Jones DR, et al. Comparison of two methods to detect publication bias in meta-analysis. *JAMA* 2006; 295: 676–680.

20. Jackson D, White IR and Riley RD. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. *Stat Med* 2012; 31: 3805–3820.

21. Wu X, Huang PY, Peng PJ, et al. Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma. *Ann Oncol* 2013; 24: 2131–2136.

22. Chen Y, Sun Y, Liang SB, et al. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China. *Cancer* 2013; 119: 2230–2238.

23. Huang PY, Cao KJ, Guo X, et al. A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma. *Oral Oncol* 2012; 48: 1038–1044.

24. Lee AW, Tung SY, Chan AT, et al. A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. *Radiother Oncol* 2011; 98: 15–22.

25. Lee AW, Tung SY, Chua DT, et al. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. *J Natl Cancer Inst* 2010; 102: 1188–1198.

26. Chen Y, Liu MZ, Liang SB, et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of China. *Int J Radiat Oncol Biol Phys* 2008; 71: 1356–1364.

27. Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. *J Clin Oncol* 2005; 23: 6730–6738.

28. Lin JC, Jan JS, Hsu CY, et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. *J Clin Oncol* 2003; 21: 631–637.

29. Chan AT, Teo PM, Ngan RK, et al. Concurrent chemotheraphy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. *J Clin Oncol* 2002; 20: 2038–2044.

30. Xu C, Zhang LH, Chen YP, et al. Chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma: a systemic review and meta-analysis of 2138 patients. *Journal of Cancer* 2017; 8: 287–297.

31. Franzen L, Funegard U, Ericson T, et al. Parotid gland function during and following radiotherapy of malignancies in the head and neck. A consecutive study of salivary flow and patient discomfort. *Eur J Cancer* 1992; 28: 457–462.

32. Rugg T, Saunders MI and Dische S. Smoking and mucosal reactions to radiotherapy. *Br J Radiol* 1990; 63: 554–556.

33. Sonis ST, Lindquist L, Van Vugt A, et al. Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor beta 3. *Cancer Res* 1994; 54: 1135–1138.
34. Petrelli NJ, Rustum YM, Bruckner H, et al. The Roswell Park Memorial Institute and Gastrointestinal Tumor Study Group phase III experience with the modulation of 5-fluorouracil by leucovorin in metastatic colorectal adenocarcinoma. *Adv Exp Med Biol* 1988; 244: 143–155.

35. Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. *Oral Oncol* 1998; 34: 39–43.

36. Lee AWM, Frer SYT, Ng WT, et al. A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity. *Cancer* 2017; 123: 4147–4157.

37. Lee AW, Ng WT, Chan LL, et al. Evolution of treatment for nasopharyngeal cancer – Success and setback in the intensity-modulated radiotherapy era. *Radiother Oncol* 2014; 110: 377–384.

38. Neal JW. The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer. *Future Oncol* 2010; 6: 1827–1832.

39. Roberts PJ, Stinchcombe TE, Der CJ, et al. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? *J Clin Oncol* 2010; 28: 4769–4777.